2m 2m 2m 2m 2m 2m 2m
VYNE THERAP (VYNE)
NASDAQ
$0.65-$0.004 (-0.62%)
Price as of Jun 23, 2026 7:00 PM EDT- $21.7MMarket Cap
- -28.89%1-Year Change
- BiotechnologyIndustry
VYNE THERAP (VYNE)
$0.65-$0.004 (-0.62%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 570,000 +13.77% | 501,000 +18.16% | 424,000 -11.11% | 477,000 -96.77% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 570,000 +13.77% | 501,000 +18.16% | 424,000 -11.11% | 477,000 -95.82% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | 16.4M -69.92% | |
Research and Development Expense | -19.2M -37.84% | -30.9M +89.77% | -16.3M -11.30% | -18.4M -26.34% | |
Depreciation and Amortization Expense | 23,000 +475.00% | 4,000 N/A | 0 -100.00% | 72,000 -33.94% | |
Total Operating Expenses | 30.3M -31.31% | 44.1M +48.70% | 29.7M -14.64% | 34.8M -56.23% | |
Operating Profit | -29.7M -31.83% | -43.6M +49.15% | -29.3M -14.69% | -34.3M -49.59% | |
Interest Income | 1.3M N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | 0 +100.00% | |
Interest Income and Expense and Net | 1.3M N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 3.0M -21.31% | 3.8M +176.62% | 1.4M +281.82% | 363,000 +368.89% | |
Income before Taxes | -26.7M -32.84% | -39.8M +42.81% | -27.9M -17.86% | -33.9M -54.01% | |
Income Taxes | 4,000 0.00% | 4,000 N/A | 0 -100.00% | 13,000 +102.90% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -26.5M -33.52% | -39.8M +40.00% | -28.5M +22.59% | -23.2M -68.35% | |
Net Income from Continuing Operations Applicable to Common | -26.7M -32.84% | -39.8M +42.82% | -27.9M -17.89% | -33.9M -53.99% | |
Basic EPS and Net Income | -0.62 -33.33% | -0.93 -66.55% | -2.78 -61.81% | -7.28 -612.68% | |
Diluted EPS and Net Income | -0.62 -33.33% | -0.93 -66.55% | -2.78 -61.81% | -7.28 -612.68% | |
Basic Weighted Average Shares | 42.8M +0.42% | 42.6M +314.57% | 10.3M +222.44% | 3.2M -93.81% | |
Diluted Weighted Average Shares | 42.8M +0.42% | 42.6M +314.57% | 10.3M +222.44% | 3.2M -93.81% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 24.0M +20.58% | 19.9M -34.92% | 30.6M -0.93% | 30.9M -26.84% | |
Short-Term Investments | 5.0M -88.02% | 41.6M -33.60% | 62.6M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 29.0M -52.84% | 61.5M -34.03% | 93.3M +201.71% | 30.9M -26.84% | |
Total Current Assets | 30.0M -53.43% | 64.4M -32.85% | 96.0M +150.72% | 38.3M -39.42% | |
Accumulated Depreciation | 27,000 +575.00% | 4,000 N/A | N/A N/A | 0 -100.00% | |
Property and Plant and Equipment and Net | 90,000 -20.35% | 113,000 N/A | N/A N/A | 0 -100.00% | |
Total Long-Term Assets | 150,000 -93.92% | 2.5M +43.32% | 1.7M N/A | 0 -100.00% | |
Total Assets | 30.2M -54.92% | 66.9M -31.51% | 97.7M +139.67% | 40.8M -39.21% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 2.4M -83.84% | 14.8M +96.59% | 7.5M +72.06% | 4.4M -76.20% | |
Total Long-Term Debt | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Long-Term Liabilities | 99,000 N/A | 0 -100.00% | 1.4M +101.71% | 700,000 N/A | |
Total Liabilities | 2.4M -83.84% | 14.8M +65.58% | 8.9M -4.23% | 9.3M -49.24% | |
Retained Earnings | -757.7M +3.62% | -731.2M +5.76% | -691.3M +4.32% | -662.7M +3.63% | |
Total Stockholders Equity | 27.8M -46.69% | 52.1M -41.30% | 88.7M +184.39% | 31.2M -35.85% | |
Total Shares Outstanding | 33.3M +124.70% | 14.8M +5.19% | 14.1M +336.54% | 3.2M -93.97% | |
Cash Flow | |||||
Cash from Operating Activities | -33.1M -2.50% | -34.0M +34.06% | -25.3M -13.22% | -29.2M -48.20% | |
Capital Expenditures | 0 -100.00% | 117,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | 37.4M +59.93% | 23.4M +140.74% | -57.4M -466.08% | 15.7M +1,425.51% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -143,000 +1.42% | -141,000 -100.17% | 82.4M +4,884.51% | 1.7M -95.84% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -5,219.12% -40.08% | -8,709.98% +26.22% | -6,900.47% -4.02% | -7,189.73% +1,459.33% | |
Return on Assets | -54.57% +12.73% | -48.40% +17.76% | -41.10% -4.54% | -43.06% -52.79% | |
Return on Equity | -66.33% +17.25% | -56.57% +19.24% | -47.44% -18.40% | -58.14% -65.85% | |
Revenue Growth | 13.77% -24.16% | 18.16% +263.44% | -11.11% -88.52% | -96.77% +225.65% | |
Current Ratio | 12.53 +188.17% | 4.35 -65.84% | 12.73 +45.72% | 8.74 +154.55% | |
Cash Ratio | 10.03 +646.11% | 1.34 -66.90% | 4.06 -42.42% | 7.06 +207.42% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow